Skip to main content
Clinical and Translational Medicine
Fig. 6 | Clinical and Translational Medicine

Fig. 6

From: Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review

Fig. 6

Disease evaluation during the treatment of pemetrexed with bevacizumab. Before treatment of pemetrexed with bevacizumab, liver metastases were assessed using CT scan and no lung lesions were found (a, d, and g). After two cycle therapy of pemetrexed with bevacizumab, metastatic nodule size in liver decreased (partial response) (b, e and h). The CT scan showed the disease progression in liver metastases after eight cycle administration of pemetrexed plus bevacizumab (c, f and i). During the entire course, there were still no metastases in bilateral lungs, mediastinum, brain and so on

Back to article page